WEBINAR: Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics – Tuesday, 26 September 2023

cnb887 dtr webinar promo bar v1 |
Register here
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • A guide to pre-validating cells for use in Organ-on-a-chip assays

      • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

      • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

      View all news

      Upcoming Events

      • AASLD 2023

      • EUROTOX 2023

      View all events

      Join the team!

      • Content Marketing Manager

      • Senior Scientist R&D

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

CN Bio appoints Dr David Hughes to board of directors

Dr David Hughes has been appointed to the board of directors, effective immediately. He will also continue with his responsibility for overseeing management of all technical projects and alliances with CN Bio partners as well as managing the internal scientific and engineering teams.

August 14, 2015

Dr David Hughes has been appointed to the board of directors, effective immediately. He will also continue with his responsibility for overseeing management of all technical projects and alliances with CN Bio partners as well as managing the internal scientific and engineering teams.

Dr Hughes joined the Company in 2010 as Head of Engineering and was promoted to Technical Director in February 2013 followed by a promotion to Chief Technology Officer in July 2014. He has been pivotal in securing contracts with leading pharmaceutical companies and has been lead principal investigator on several UK, EU and US grants including currently the EU FP7 BIO-MIMETICS project. As co-principal investigator on a $26 Mi US DARPA contract, Dr Hughes has contributed to the strategic direction of this program as well as leading the company’s participation and delivery of milestones under the contract. Prior to joining CN Bio, Dr Hughes graduated from the University of Oxford with a Masters in Engineering Science and Doctorate in Chemical Engineering. After that he spent three years in industry at GSK.

Maureen Coleman, Chairman of CN Bio said ” On behalf of the board of CN Bio Innovations I am delighted to announce that Dr David Hughes has been appointed as a director of the company and will join the board immediately. This clearly recognises David’s growing contribution not only in leading the growth in excellence of science in the company but to its ongoing business and commercial development.”

Category iconBusiness

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023

Upcoming events

AASLD 2023 November 10-14, 2023

EUROTOX 2023 September 10-13, 2023